Evidence map›Paper›PMID 25012661›Full record

ArticleThe Journal of biological chemistry2014

Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.

Stefan Baertschi, Nina Baur, Valerie Lueders-Lefevre, Johannes Voshol, Hansjoerg Keller

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Changes in bone mineral density in Down syndrome individuals: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Positive and Negative Regulators of Sclerostin Expression.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.International journal of molecular sciences · 2019
    Review
  12. Review
  13. The Bromodomain InhibitorInternational journal of molecular sciences · 2018
    Article
  14. Article
  15. Regulation of Bone Remodeling by Parathyroid Hormone.Cold Spring Harbor perspectives in medicine · 2018
    Review
  16. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Stefan BaertschiFrom the Musculoskeletal Disease Area and.
Nina BaurDevelopmental and Molecular Pathways, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
Valerie Lueders-LefevreFrom the Musculoskeletal Disease Area and.
Johannes VosholDevelopmental and Molecular Pathways, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
Hansjoerg KellerFrom the Musculoskeletal Disease Area and hansjoerg.keller@novartis.com.
Institute for Musculoskeletal Health · AUNovartis Institutes for BioMedical ResearchNovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult bone mass is controlled by the bone formation repressor sclerostin (SOST). Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves SOST expression reduction by inhibiting myocyte enhancer factor 2 (MEF2), which activates a distant bone enhancer. Here, we extended our SOST gene regulation studies by analyzing a role of class I and IIa histone deacetylases (HDACs), which are known regulators of MEF2s. Expression analysis using quantitative PCR (qPCR) showed high expression of HDACs 1 and 2, lower amounts of HDACs 3, 5, and 7, low amounts of HDAC4, and no expression of HDACs 8 and 9 in constitutively SOST-expressing UMR106 osteocytic cells. PTH-induced Sost suppression was associated with specific rapid nuclear accumulation of HDAC5 and co-localization with MEF2s in nuclear speckles requiring serine residues 259 and 498, whose phosphorylations control nucleocytoplasmic shuttling. Increasing nuclear levels of HDAC5 in UMR106 by blocking nuclear export with leptomycin B (LepB) or overexpression in transient transfection assays inhibited endogenous Sost transcription and reporter gene expression, respectively. This repressor effect of HDAC5 did not require catalytic activity using specific HDAC inhibitors. In contrast, inhibition of class I HDAC activities and expression using RNA interference suppressed constitutive Sost expression in UMR106 cells. An unbiased comprehensive search for involved HDAC targets using an acetylome analysis revealed several non-histone proteins as candidates. These findings suggest that PTH-mediated Sost repression involves nuclear accumulation of HDAC inhibiting the MEF2-dependent Sost bone enhancer, and class I HDACs are required for constitutive Sost expression in osteocytes.

Indexed as

AcetylationAnimalsBone Morphogenetic ProteinsCell Line, TumorCell NucleusElectrophoresis, Polyacrylamide GelFatty Acids, UnsaturatedGene Expression RegulationGenetic MarkersGreen Fluorescent ProteinsHistone Deacetylase InhibitorsHistone DeacetylasesHumansMEF2 Transcription FactorsMicroscopy, ConfocalMicroscopy, FluorescenceBone Morphogenetic ProteinsFatty Acids, UnsaturatedGenetic MarkersGreen Fluorescent ProteinsHdac5 protein, ratHistone Deacetylase InhibitorsHistone Deacetylasesleptomycin BMEF2 Transcription FactorsParathyroid HormoneSost protein, ratGene RegulationHistone Deacetylase (HDAC)Parathyroid HormoneSclerostinTranscriptional CoactivatorTranscription Corepressor

Identifiers

PMID25012661
PMCPMC4155667
OpenAlexW2044520095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.